Euglycemic diabetic ketoacidosis induced by dapagliflozin

  • At: 2017 FIP Congress in Seoul (South Korea)
  • Type: Poster
  • By: LIN, Chia-Fang (Chang Gung Memorial Hosipital, Taoyuan, Taiwan, Department of Pharmacy, Taoyuan, China Taiwan)
  • Co-author(s): Chia-Fang Lin: Department of Pharmacy, Chang Gung Memorial Hosipital, Taoyuan, Taiwan, Taoyuan, Taiwan, Province of China
    Hsuan-Ling Hsiao: Department of Pharmacy, Chang Gung Memorial Hosipital, Taoyuan, Taiwan, Taoyuan, Taiwan, Province of China
    Tzu-Cheng Tsai: Department of Pharmacy, Chang Gung Memorial Hosipital, Taoyuan, Taiwan, Taoyuan, Taiwan, Province of China
    Shin-Tarng Deng: Department of Pharmacy, Chang Gung Memorial Hosipital, Taoyuan, Taiwan, Taoyuan, Taiwan, Province of China
  • Abstract:

    Background

    Sodium-glucose cotransporter-2 (SGLT2) inhibitors are the newest class of oral antihyperglycemic medications to be approved for the treatment of patients with type 2 diabetes mellitus as one of second-line therapy options. Recent evidence warns of an increased risk of diabetic ketoacidosis (DKA) with nonspecifically mild to moderate..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login